Tools and devices for telerehabilitation in pediatric and adult cystic fibrosis patients: a scoping review
Tools and devices for telerehabilitation in pediatric and adult cystic fibrosis patients: a scoping review

Tools and devices for telerehabilitation in pediatric and adult cystic fibrosis patients: a scoping review

Disabil Rehabil Assist Technol. 2025 Feb 10:1-8. doi: 10.1080/17483107.2025.2463548. Online ahead of print.

ABSTRACT

BACKGROUND: Cystic fibrosis (CF) is a genetic disorder affecting multiple organs, primarily the lungs. Rehabilitation is crucial in managing respiratory symptoms. Telerehabilitation, which provides remote rehabilitation services via digital platforms, gained importance during the COVID-19 pandemic. Despite its growing use, there is little clarity on the available tools and devices for CF telerehabilitation.

OBJECTIVE: This scoping review aims to map the existing tools and devices used in telerehabilitation for pediatric and adult CF patients.

METHODS: The review was conducted following the Joanna Briggs Institute methodology, using the PRISMA-ScR checklist. Comprehensive searches were performed across seven databases, alongside grey literature. Studies involving CF patients and telerehabilitation interventions were included. Data were extracted and analyzed both numerically and thematically.

RESULTS: Eighteen studies were included, involving 622 CF patients. The review identified 10 platforms, seven telemonitoring devices, and three rehabilitation devices. Most studies focused on motor rehabilitation with individual, synchronous sessions. Commonly used platforms included Zoom, Skype, and Google Meet, while only three studies used platforms specifically designed for CF.

CONCLUSIONS: Telerehabilitation for CF is in its early stages and less developed than for other conditions. There is a need for dedicated platforms and devices that address CF patients’ specific motor and respiratory needs. Future efforts should focus on developing these tools to improve patient engagement and outcomes.

PMID:39928374 | DOI:10.1080/17483107.2025.2463548